Durvalumab combined with concurrent chemoradiotherapy in patients with limited-stage small cell lung cancer: A prospective, single-arm, phase 2 clinical trial - PubMed
4 hours ago
- #immunotherapy
- #chemoradiotherapy
- #small cell lung cancer
- Durvalumab combined with concurrent chemoradiotherapy (cCRT) was studied in a phase 2 trial for limited-stage small cell lung cancer (LS-SCLC).
- The trial included 51 patients, with a median follow-up of 32.0 months, showing 1-, 2-, and 3-year PFS rates of 56.9%, 35.9%, and 28.2%, respectively.
- The 1-, 2-, and 3-year OS rates were 88.1%, 68.6%, and 49.6%, respectively, with a median OS of 32.0 months.
- Grade 3 or 4 adverse events occurred in 33.4% of patients, with 7 being immune-related.
- The study concluded that durvalumab with cCRT was well-tolerated and showed encouraging efficacy for LS-SCLC.